Key Players
Competitive Landscape
Four supplier models compete in cholangiocarcinoma: first-line immunotherapy groups, mutation-directed developers, companion-diagnostic companies and regional commercialization partners.
Since 2025 clinical investment has shifted toward comparative first-line trials and commercial routes for rare alterations. Incyte presented phase 3 FIGHT-302 results in June 2026 while Partner Therapeutics received FDA approval for Bizengri in May 2026. Treatment centers now compare label scope, biomarker requirements and treatment-line fit before price during formulary review.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Incyte reported phase 3 FIGHT-302 results in June 2026 with 47% objective responses versus 15.5% for chemotherapy. | Oncologists need comparative evidence before placing FGFR2 testing ahead of standard first-line chemotherapy for eligible patients. | Mutation-directed medicines are entering first-line comparative trials instead of remaining later-line options for selected patients. | Revenue depends on identifying FGFR2-rearranged patients before treatment and routing them into specialist care pathways. |
| Partner Therapeutics received FDA approval for Bizengri in May 2026 following 36.8% objective responses among evaluable patients. | Specialist centers need an approved route for ultra-rare NRG1-fusion disease following prior systemic treatment pathways. | Commercial competition is dividing into small alteration-defined groups with separate testing and later-line commercial labels. | Specialty distribution and molecular screening can capture rare fusion-defined treatment demand beyond broad commercial regimens. |
| Jazz received conditional European authorization for Ziihera in June 2025 for previously treated HER2-positive advanced biliary tract cancer. | European oncology centers need standardized HER2 results before selecting approved later-line treatment for eligible patients. | HER2 testing is becoming a commercial gateway for alteration-directed treatment across European specialist oncology systems. | Pathology education and reliable specialist supply can expand European treatment volume among referred regional patients. |
Merck and AstraZeneca compete through approved first-line chemoimmunotherapy, although neither company recorded a new exact-market approval during 2025-2026.
Source: Future Market Insights, Cholangiocarcinoma Market and Biliary Tract Cancers Treatment Market Reports, 2026-2036.
Incyte and Partner cover FGFR2-directed and NRG1-directed therapies while Jazz supplies HER2-directed treatment and Roche supports matched companion testing across United States and European pathways.
Who leads the cholangiocarcinoma market?
Merck and AstraZeneca anchor first-line competition through approved chemoimmunotherapy, while Incyte holds a distinct FGFR2 position supported by comparative FIGHT-302 evidence.
Which companies have documented regulatory or diagnostic approvals?
Roche holds FDA and CE IVDR HER2 companion-diagnostic approvals, while Jazz and Partner hold later-line treatment approvals for HER2-positive and NRG1-fusion disease.
Which companies provide biomarker-selected cholangiocarcinoma medicines?
Incyte and Taiho supply FGFR2 inhibitors, Servier supplies an IDH1 inhibitor and Jazz or Partner address HER2-positive or NRG1-fusion disease.
Which companies serve North America and Europe?
Jazz and Roche serve United States and European pathways through Ziihera and matched HER2 testing, while Merck maintains approved European first-line coverage.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Incyte Corporation | United States | Pemazyre serves FGFR2-rearranged disease and FIGHT-302 adds first-line phase 3 evidence. |
| Merck & Co., Inc. | Europe | Keytruda plus chemotherapy treats first-line advanced biliary tract cancer in Europe. |
| AstraZeneca PLC | United States | Imfinzi plus chemotherapy treats first-line advanced biliary tract cancer in the United States. |
| F. Hoffmann-La Roche Ltd. | United States and Europe | PATHWAY and VENTANA HER2 assays identify patients eligible for Ziihera. |
| Servier Pharmaceuticals LLC | United States and Germany | Tibsovo treats IDH1-mutated disease and a first-line combination study remains active. |
| Taiho Pharmaceutical Co., Ltd. | United States | Lytgobi treats previously treated FGFR2-rearranged intrahepatic cholangiocarcinoma. |
| Jazz Pharmaceuticals plc | United States and Europe | Ziihera treats HER2-positive disease and HERIZON-BTC-302 evaluates first-line use. |
| Partner Therapeutics, Inc. | United States | Bizengri treats NRG1-fusion disease following prior systemic therapy. |
Research Methodology
The companies illustrate cholangiocarcinoma competition and do not represent a ranking of commercial performance or market share. Inclusion requires current evidence of an approved medicine, registrational program or exact-market diagnostic for biliary tract cancer. Evidence comes from company newsrooms, regulator records, trial registries and official filings tied to the named legal entity. The 38.0% targeted therapy share is an FMI estimate for 2026 and does not measure individual company revenue.
